Multicenter Phase II study of modified FOLFOX7(combination chemotherapy of infusional 5-FU/l-Leucovorin and intermittent Oxaliplatin)with bevacizumab in the first-line therapy of colorectal cancer - CRAFT trial- - Avastin plus intermittent mFOLFOX7 therapy in advanced colorectal cancer-CRAFT trial- Multicenter Phase II study

Epidemiological and Clinical Research Information Network (ECRIN)0 个研究点目标入组 50 人开始时间: 2009年9月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1, Need to drain malignant coelomic fluid 2, Symptomatic brain metastasis 3, Multiple primary cancer within 5years 4, With suspected complication of arterial thromboembolism (ex:cerebrovascular disease)or experienced thrombosis within 1year/ twice of thrombosis 5, Any surgical treatments including skin-open biopsy, trauma surgery and other more intensive surgery within 4 weeks. 6, Planning a surgery during the study. 7, Administering antithrombotic drug within 14 days. 8, Need to administrate or having anti-platelets therapy (including aspirin and NSAIDS) 9, Bleeding tendency(including hemoptysis) or coagulation disorder (INR>=1.5) 10, Uncontrolled complication of peptic ulcer. 11, Current or previous (within one year) history of GI perforation 12, Serious renal complications or having 2+ uric protein 13, Uncontrolled High blood pressure. 14, Symptomatic or symptomatic or asymptomatic but treated heart disease but treated heart disease 15, Serious drug hypersensitivity or a history of drug allergy (5FU, oxalipratin, Levofolinate calcium) 16, Experienced adverse drug reaction caused by fluoropyrimidines with suspected dihydropyrimidine dehydrogenase (DPD) deficiency 17, Uncontrolled diarrhea 18, Peripheral neuropathy(Grade 1=<) 19, Uncontrolled infection 20, Pregnant women, possibly pregnant women, wishing to become pregnant, and nursing mothers 21, Previously treated with bevacizumab or oxaliplatin 22, Other conditions not suitable for this study

发起方

Epidemiological and Clinical Research Information Network (ECRIN)